When was ProtAb founded?

ProtAb was founded in August 2005.

What is ProtAb's current operational status?

ProtAb is currently inactive, as of December 2017.

Who are the lead investors in ProtAb's A Round funding?

ProtAb's A Round funding in April 2010 was led by Pontifax and Clal Biotechnology Industries (CBI).

What was the total amount raised by ProtAb?

ProtAb has raised a total of $4,000,000 USD.

Who is the founder of ProtAb?

Yaakov Naparstek is the founder of ProtAb.

ProtAb

Develops therapeutic agents that modulate cytokine regulation to address autoimmune and inflammatory diseases.

Non Active, Dec 2017

Series A Jerusalem, Israel Founded 2005

Last updated 2026-07-19

Raised $1.5M Series A led by Pontifax, Apr 2010
Raised $1.9M grant, Jan 1970
Raised grant, 2005

Total raised

$4.0M

Last: A Round 2010-04

Stage

Series A

Founded

2005

Headcount

Jerusalem, Israel

Sector

—

About

ProtAb Ltd is focused on the development of therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. The companys first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA). ProtAb operates as a subsidiary of Hadasit Bio-Holdings Ltd (HBL). HBL is a publicly traded subsidiary of Hadasit Ltd, the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel.

Funding history · 3 rounds · $4.0M total

2010-04

A Round $1.5M Globes, April 2010

★ Pontifax★ Clal Biotechnology Industries (CBI)Hadasit Bio-Holdings

2005

Grant Undisclosed Startup Nation Finder, Jan 2018

Office of the Chief Scientist

1970-01

Grant $1.9M Finder grant (one-time migration 2026-07)

Q&A

What is ProtAb's primary focus?: ProtAb Ltd focuses on developing therapeutic agents that modulate cytokine regulation to treat autoimmune and inflammatory diseases.
What is ProtAb's lead product?: ProtAb's first product is Prozumab, a monoclonal antibody with a novel mechanism of action, currently in late-stage preclinical development for inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA).
When was ProtAb founded?: ProtAb was founded in August 2005.
What is ProtAb's current operational status?: ProtAb is currently inactive, as of December 2017.
Who are the lead investors in ProtAb's A Round funding?: ProtAb's A Round funding in April 2010 was led by Pontifax and Clal Biotechnology Industries (CBI).
What was the total amount raised by ProtAb?: ProtAb has raised a total of $4,000,000 USD.
Who is the founder of ProtAb?: Yaakov Naparstek is the founder of ProtAb.

Team · 1

Yaakov Naparstek

Founder · Founder

LinkedIn ↗

Sectors & technology

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

Biologicals

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2B

Highlights

1 Patents

Identifiers & details

Legal name	ProtAb Ltd
Founded	2005-8
Employees (exact)	6
Status reason	Non Active, Dec 2017